The nasopharyngeal swab samples were obtained by a medical team of 14 doctors (Chuancai Xu, Zhisong He, Wei Lei, Li Chen, Dan Shen, Xiaofei Wang, Deyu Xu, Jinzhou Zhu, Jindan Kong, Yao Wei, Daguo Zhao, Ting Xue, Ying Xu, Huayu Xu). Ltd, Zhengzhou, China) were summarized on the day of admission. Nasopharyngeal swab SARS-CoV-2 RNA test results, SARS-CoV-2 nucleocapsid gene cycle threshold (ct) values, complete blood counts, coagulation profiles, hypersensitive C-reactive protein (Hs-CRP) levels, serum biochemical parameters, interleukin-6 (IL-6) levels, chest computed tomography (CT), and levels of specific serum IgM and IgG antibodies of SARS-CoV-2 (Autobio Co. SARS-CoV-2 infection was confirmed by a positive SARS-CoV-2 RNA test from nasopharyngeal swabs using a reverse transcription quantitative PCR method according to the manufacturer’s protocol (Liferiver Co. Because our research was retrospective and noninterventional, it was granted an ethics exemption from the ethics committee of the Yangzhou Third People’s Hospital. Demographic and clinical variables were obtained from electronic records. We conducted a retrospective study of 147 COVID-19 patients with mild to moderate illness who were hospitalized in the Third People’s Hospital of Yangzhou from 7 to 20 August 2021. In this retrospective study, we reported the clinical characteristics of 147 hospitalized patients with COVID-19 to evaluate the role of inactivated vaccines on viral RNA shedding and to analyze laboratory tests of patients to optimize the clinical management of breakthrough infections. To date, little information is available on the effect of inactivated vaccines on viral RNA shedding. The duration of viral RNA shedding is critical for determining therapeutic strategies to manage the disease and for making decisions regarding the patient’s discharge. Hence, there is an urgent need to elucidate the role of inactivated vaccines among breakthrough infections. Īt present, the effectiveness of inactivated vaccines for COVID-19 in fully immunized patients in a real-world population is poorly understood. Nevertheless, compared with unvaccinated (UV) individuals, the hospitalization rate and COVID-19-related mortality of fully vaccinated (FV) individuals were significantly lower. In Qatar, the effective rates of BNT162b2 and mRNA-1273 against infection with the delta variant were 51.9% and 73.1%, respectively. A test negative case‒control study in Brazil showed that the effective rates of CoronaVac in older adults against symptomatic disease and death caused by the gamma mutant were 59% and 83.9%, respectively. A test negative case‒control design to estimate the effectiveness of the BNT162b2 and ChAdOx1nCoV-19 vaccines against symptomatic disease caused by the delta variant found that the effectiveness of two doses were 88.0% and 67.0%, respectively. Mutations in the spike (S) gene of SARS-CoV-2 variants, especially at neutralizing antibody-binding sites, result in the most severe reduction in the neutralization ability induced by mRNA and inactivated vaccines. CoronaVac is an inactivated SARS-CoV-2 vaccine with a variable effectiveness rate, ranging from 50.65% to 83.50%, against symptomatic COVID-19. However, there was a certain degree of reduction in the effectiveness of the vaccines in populations with comorbidities. The two SARS-CoV-2 mRNA vaccines, BNT162b2 and mRNA-1273, have been 94%-95% effective in preventing symptomatic coronavirus disease 2019 (COVID-19). Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant infections are rising rapidly worldwide. Inactivated vaccines may shorten viral RNA shedding in breakthrough infected patients who have mild-to-moderate illness and may improve the ability of the host to generate specific antibodies to infection. The median titers of SARS-CoV-2-specific IgG and IgM were significantly higher in the FV (12.29 S/co and 0.3 S/co, respectively) and PV (0.68 S/co and 0.12 S/co, respectively) groups than in the UV group (0.06 S/co and 0.04 S/co ) (adjusted P < 0.001 and adjusted P = 0.008, respectively). The median duration of viral RNA shedding was shorter in the FV (12 days) and PV (13 days) groups than in the UV group (15 days) (adjusted P < 0.001 and adjusted P = 0.23, respectively). We collected data of 147 coronavirus disease 2019 (COVID-19) patients with mild-to-moderate illness who were hospitalized in the Third People’s Hospital of Yangzhou from 7 to 20 August 2021 and analyzed the differences in symptoms and laboratory tests among fully vaccinated (FV), partially vaccinated (PV) and unvaccinated (UV) patients. At present, the role of inactivated vaccines in viral RNA shedding among Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) breakthrough infections is still unknown.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |